Patents by Inventor Philip Sizer

Philip Sizer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS
    Publication number: 20210316000
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Application
    Filed: November 11, 2018
    Publication date: October 14, 2021
    Applicant: Altimmune UK Limited
    Inventors: Dominique Bonnet, Carlton Brown, Bertrand Georges, Philip Sizer
  • INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS
    Publication number: 20190142951
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Application
    Filed: November 11, 2018
    Publication date: May 16, 2019
    Applicant: Altimmune UK Limited
    Inventors: Dominique Bonnet, Carlton Brown, Bertrand Georges, Philip Sizer
  • Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
    Patent number: 7959931
    Abstract: Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: June 14, 2011
    Assignee: Novartis AG
    Inventors: Anthony Colegate, Philip Sizer
  • INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO ALUMINIUM ADJUVANTS
    Publication number: 20090202590
    Abstract: Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt.
    Type: Application
    Filed: November 6, 2006
    Publication date: August 13, 2009
    Applicant: NOVARTIS VACCINES AND DIGNOSTICS SRL
    Inventors: Anthony Colegate, Philip Sizer
  • Method of removing endotoxin from vaccines
    Patent number: 7226775
    Abstract: A method of removing bacterial endotoxin from a pharmaceutical process solution is disclosed. In one embodiment, the method comprises treating the solution with a surfactant effective to dissociate the endotoxin from a pharmaceutical drug or vaccine substance in the solution, and then filtering the solution through a molecular cut-off filter having a pore size effective to retain the pharmaceutical drug or vaccine substance but allow the dissociated bacterial endotoxin to pass therethrough.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: June 5, 2007
    Assignee: Medeva Europe Limited
    Inventors: Bridget Kathleen Mapleson, Philip Sizer
  • Antigen delivery vectors and constructs
    Publication number: 20060013820
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Application
    Filed: April 1, 2005
    Publication date: January 19, 2006
    Inventors: Dominique Bonnet, Carlton Brown, Bertrand Georges, Philip Sizer
  • Method of removing endotoxin from vaccines
    Publication number: 20010053366
    Abstract: A method of removing bacterial endotoxin from a pharmaceutical process solution is disclosed. In one embodiment, the method comprises treating the solution with a surfactant effective to dissociate the endotoxin from a pharmaceutical drug or vaccine substance in the solution, and then filtering the solution through a molecular cut-off filter having a pore size effective to retain the pharmaceutical drug or vaccine substance but allow the dissociated bacterial endotoxin to pass therethrough.
    Type: Application
    Filed: March 12, 2001
    Publication date: December 20, 2001
    Inventors: Bridget Kathleen Mapleson, Philip Sizer